Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

By Chan Phylinda   Nutt John   Holford Nicholas  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 3-4, 2005-08 ,pp. : 459-484

Springer Publishing Company

Access to resources Recommend Favorite

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A.   Hauser R.A.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite

Levodopa-Induced Response Fluctuations in Patients with Parkinson’s Disease: Strategies for Management

By van Laar T.  

CNS Drugs, Vol. 17, Iss. 7, 2003-01 ,pp. : 475-489

Adis International

Access to resources Recommend Favorite

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

By Stocchi Fabrizio  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1399-1407

Informa Healthcare

Access to resources Recommend Favorite

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinson’s Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

By Fulvio Bracco  

CNS Drugs, Vol. 18, Iss. 11, 2004-01 ,pp. : 733-746

Adis International

Access to resources Recommend Favorite